Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ZIOP

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

ZIOPHARM Oncology logo

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

Key Stats

Today's Range
N/A
50-Day Range
$0.82
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOP Stock News Headlines

Best Global Universities for Oncology
Alx Oncology Holdings (ALXO)
Financial Prophecy
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
CG Oncology Inc
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
WBSPH 2024 - Oncology
See More Headlines

ZIOP Stock Analysis - Frequently Asked Questions

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $0.40 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIOPHARM Oncology investors own include Precigen (PGEN), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN) and CorMedix (CRMD).

Company Calendar

Last Earnings
11/08/2021
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZIOP
CUSIP
98973P10
Employees
105
Year Founded
2005

Profitability

Net Income
$-79,980,000.00
Pretax Margin
-22,544.97%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.58 per share

Miscellaneous

Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:ZIOP) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners